česky | english | sitemap

Czech Gynaecological and Obstetrical Society | Ministry of Health | Institute of Biostatistics and Analyses, Masaryk University
GlaxoSmithKline     Roche |

Other sources of information
Cervical cytology (in Czech)www.cipek.cz
Cervical cytology
Cancer Screening in the European Unionec.europa.eu
Cancer Screening in the European Union (2017)
[ 10,6 MB]
SVOD - Epidemiology of malignant tumours in the Czech Republicwww.svod.cz
Epidemiology of malignant tumours
in the Czech Republic
NCI Bethesda System
HPV College


Data collection for information support of Czech cancer screening programmes

The system for information support is a necessary part of organised cancer screening programmes. The Council of the European Union recommends [1] that member states “regularly monitor the process and outcome of organised screening and report these results quickly to the public and the personnel providing the screening.” Information system should be therefore able to “collect, manage and evaluate data on all screening tests, assessment and final diagnoses.” Components of the system operating in the Czech Republic include monitoring of cancer burden, monitoring of screening process using clinical data, and monitoring of screening process using administrative data (see Fig. 1).

Expert medical societies responsible for the management of screening and diagnosis of preventable cancers (breast cancer, colorectal cancer and cervical cancer) have agreed with the Czech Ministry of Health to appoint an academic institute responsible for coordination of the information support, namely operating cancer screening registries and monitoring of the programmes using all of the above-mentioned sources of data; this role has been attributed to the Institute of Biostatistics and Analyses at Masaryk University in Brno, Czech Republic (IBA MU).

IBA MU performs a regular evaluation of data in the Czech National Cancer Registry (CNCR), making it freely available at www.svod.cz [2]. The system for monitoring of breast, colorectal, and cervical cancer screening programmes has been established according to international recommendations, as provided by the European Commission [3–5]. As required by the EU Council Recommendation on Cancer Screening, data on screening tests and the following diagnostic procedures is regularly collected in all screening centres (i.e., health care facilities recommended for cancer screening examinations). The information system enables the collected data to be analysed and published, thus allowing a thorough quality control by the programme management, as well as the publication of programme performance and the results on dedicated cancer prevention websites (www.mamo.cz, www.kolorektum.cz, www.cervix.cz).

Figure 1: Data collection in Czech cancer screening programmes information support.

Czech National Cervical Screening Programme

Preventive pap-smear testing has been used in the Czech Republic since the 1960s. As a part of the annual regular preventive check-up, a sample of cells from the uterine cervix is collected by the gynaecologist. The sample is then subjected to an examination by screening cytology. Gynaecological prevention checkups are available to all women aged over 15 years.

This prevention, however, was not organised as a nationwide screening programme. In 2007, the Czech Ministry of Health issued a list of required criteria to be met by accredited screening cytology centres. In particular, this directive specified proper technical equipment, requirements on personnel, quality control mechanisms, and basic data audit requirements. A network of screening cervical cytology centres was established in January 2008. The programme is overseen by the Cervical Cancer Screening Committee at the Czech Ministry of Health.

In 2008, a proposal of the project documentation was approved that defined processes necessary in transforming the existing opportunistic prevention into an organised programme. The documentation included a description of the screening process and data collection. The pilot project of data collection was started in 2009 after establishing the central database – Cervical Cancer Screening Registry (run by the IBA MU). The key part of the screening process are cytology laboratories recommended for the cervical cancer screening, which provide examinations of screening Pap smears. These labs operate their own database systems recording results of cytology and pathology examinations. The source of data are standard cytology request forms (provided to the lab by the gynaecologist), results of cytology examination itself, and histopathology return form (provided to the lab by the gynaecologist or available in the laboratory itself). Each cytology examination has its own record in the central database, which stores data collected from each cytology laboratory.


  1. The Council of the European Union. Council recommendation of 2 December 2003 on cancer screening (2003/878/EC) [online]. 2003 [28/09/2012]. On-line available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:327:0034:0038:EN:PDF
  2. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. SVOD.cz -Epidemiology of Malignant Tumours in the Czech Republic [online]. Masaryk University; 2007 [12.7.2013]. On-line available: http://www.svod.cz. ISSN 1802-8861
  3. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L, et al., editors. European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed. Luxembourg: Office for Official Publications of the EC; 2006.
  4. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening, 2nd ed. Luxembourg: European Communities; 2008.
  5. Segnan N, Patnick J, von Karsa L, editors. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: Publications Office of the European Union; 2010.


Last updated on 6 February 2014